Demoxepam

Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [3H]tryptophan binding to rat hepatic nuclei[1][2][3].

Product Specifications

CAS Number

[963-39-3]

UNSPSC

12352005

Hazard Statement

H302

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/demoxepam.html

Purity

98.39

Solubility

10 mM in DMSO

Smiles

O=C1NC2=CC=C(Cl)C=C2C(C3=CC=CC=C3)=[N+]([O-])C1

Molecular Formula

C15H11ClN2O2

Molecular Weight

286.71

Precautions

H302

References & Citations

[1]Moustapha Ouédraogo, et al. In vitro cytotoxicity study of oxaziridines generated after chlordiazepoxide, demoxepam, and desmethylchlordiazepoxide UV irradiation. Drug Chem Toxicol. 2009;32 (4) :417-23.|[2]Gregory G Sarris, et al. Demoxepam Derivatization and GC-MS Analysis Produces Erroneous Nordiazepam and Oxazepam Results. J Anal Toxicol. 2019 Jun 1;43 (5) :406-410.|[3]Sidransky, H., et al., (1992) . Inhibitory effect of demoxepam on tryptophan binding to rat hepatic nuclei. Biochemical medicine and metabolic biology, 47 (3), 270–273. |[4]Vinkers, C. H., et al., (2010) . The rapid hydrolysis of chlordiazepoxide to demoxepam may affect the outcome of chronic osmotic minipump studies. Psychopharmacology, 208 (4), 555–562.